Yuan Yuan, MD, PhD, discusses T-DXd plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.
Back
Dr Yuan on Dual-Pathway Targeted Strategies in ER+/HER2+ Breast Cancer
Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive/HER2-positive metastatic disease.
Dr Yuan on Dual-Pathway Targeted Strategies in ER+/HER2+ Breast Cancer
Episodes
All
All
EP. 2: Dr Yuan on Intracranial Activity With T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer
Yuan Yuan, MD, PhD, reports the intracranial efficacy of T-DXd plus pertuzumab in HER2-positive breast cancer, per results from the DESTINY-Breast12 study.
Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive, HER2-positive metastatic disease.
Yuan Yuan, MD, PhD, discusses a new treatment approach involving induction T-DXd followed by trastuzumab/pertuzumab maintenance in HER2-positive disease.
Yuan Yuan, MD, PhD, discusses questions regarding the potential benefit of T-DXd in first line regimens for HER2-positive breast cancer with CNS metastases.
Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
4
Five Under 5: Top Oncology Videos for the Week of 8/9
5